Consult
Log In
Menu
Consult
Log in

by PierianDx, on July 29, 2021

Our Employee Spotlight shines a light on the uniqueness of the PierianDx team. Our commitment to precision medicine and ensuring the success of our customers is the common theme amongst our team. But beyond that,  we’re as diverse and unique as they come. If you would like to join our team, click here to view our open positions.

Read Story
Topics:Blog

by PierianDx, on June 9, 2021

“It’s funny what a good hackathon can do,” remarked Ankita Parikh, Senior Software Engineer at PierianDx. “I woke up feeling sad because there were no more issues to resolve!” Ankita’s sentiment was matched by about 50 of her coworkers as they participated in the second annual PierianDx Hackathon. From April 22-25, over 50 PierianDx team members in Pune, India and St. Louis, Missouri set out to discover, conceptualize, and prototype solutions for our customers. Over the course of three days -- and several sleepless nights--developers, and other staff members self-organized in cross functional teams across different departments from both our offices, prioritized challenges, and promptly got to work.  

Read Story
Topics:Blog

by PierianDx, on March 22, 2021

According to recent estimates, almost 80% of cancer patients (1,2) in the United States are diagnosed and treated in community cancer centers. With incredibly busy schedules, providers at these centers often struggle to offer to most up-to-date, cutting edge care.

Read Story
Topics:Blog

by PierianDx, on August 11, 2020

Comprehensive genomic profiling is emerging as a powerful tool in our arsenal to treat cancer. It’s easy to see why: with a minimal amount of sample, clinicians are able to identify all four types of genetic alterations across a large set of genes with known relevance to cancer. When you consider that up to 90% of patients who undergo comprehensive genomic profiling may have an actionable genetic alteration1-6 , you begin to understand how this new diagnostic tool can revolutionize cancer care.  

Read Story
Topics:Blog

by PierianDx, on August 3, 2020

Next generation sequencing continues to gain traction as a standard of care as it becomes less complex and less costly. Targeted sequencing, in which only a subset of genes are enriched and amplified for sequencing, is especially cost effective. Clinicians are using the technique to more quickly provide answers to oncologists to ensure that patients actually get the right therapy. 

Read Story
Topics:Blog

by PierianDx, on June 25, 2020

What is the one thing we must do if we are to give complex disease a run for its money? According to Rakesh Nagarajan, MD, PhD, Founder and Executive Chairman at PierianDx, we must amass and share patient data in a safe and compliant manner to answer complex questions more quickly. In this informational interview, Dr. Nagarajan sits down with VOL reporter, Daiva Sen, to discuss the importance of data sharing and other topics, including: 

  • Universal healthcare systems and the importance of accessibility
  • Genomic data sharing, regulation, and privacy
  • Real-world evidence in managing patient care

To learn more, watch the video.

Read Story
Topics:Blog

by PierianDx, on May 28, 2020

Precision medicine continues to gain traction, and increasingly, clinicians are turning to comprehensive genomic profiling to match the right drug to a patient using information about that patient’s genetic mutations.

Read Story
Topics:Blog

by PierianDx Team Member, on April 7, 2020

Precision medicine is the ability to use genomic information to optimize diagnosis and treatment and provide better outcomes for patients. We Know Precision Medicine is a series of blog posts and articles about the people of PierianDx and how we know precision medicine through our expertise and personal experiences. In this blog post, a PierianDx employee shares what it’s like to live with cancer in the time of COVID-19.

Read Story
Topics:Blog

by PierianDx, on March 18, 2020

Sequencing technology advances, such as comprehensive profiling assays, lower costs, and improved reimbursement continue to drive the adoption of clinical next generation sequencing. Organizations, such as Foundation Medicine, provide comprehensive NGS tests and resulting reports that physicians can order for patients with solid tumors. However, an increasing number of academic medical centers and healthcare organizations are opting to internalize their NGS testing program because it gives them greater control over tissue, turnaround time, and it provides more opportunity for interaction between ordering physicians and those running the tests. 

Arriving at the decision to build an internal NGS test menu is often the first hurdle for healthcare organizations. What comes next can be even more challenging.

Rakesh Nagarajan, MD, PhD, Founder and Executive Chairman PierianDx, recently sat down with Joseph Anderson, MD, The Personalized Diagnostics Podcast, to discuss the advent of personalized medicine and what it will take to make clinical NGS a routine part of healthcare. In particular, Rakesh and Joe discuss:

  • How the industry is shifting to larger (50+ gene) panels
  • How to think about bringing a test online and addressing complex components, such as validation
  • How to address the variant interpretation bottleneck

To learn more, listen to the podcast.

Read Story
Topics:Blog

by PierianDx, on March 20, 2019

PierianDx will be highlighting germline features of its genomics technology platform at the American College of Medical Genetics and Genomics (ACMG) annual meeting April 2-6 in Seattle, Washington. 

Read Story
Topics:Blog

by PierianDx, on February 26, 2019

Genomic tests that use next generation sequencing (NGS) technology are on the rise, and there’s a growing trend for hospitals to insource these tests to improve turnaround time and reduce costs. However, these tests can be challenging to implement. Challenges include lack of bioinformatics expertise, the cost and expense of deploying a new test, and reimbursement, to name a few.

Read Story
Topics:Blog

by PierianDx, on February 25, 2019

In just under 15 years, next generation sequencing (NGS) has evolved from a technology that only an exclusive few research laboratories had access to, to one in use by nearly 300 clinical laboratories worldwide.1,2

Read Story
Topics:Blog